VTYX (Ventyx Biosciences Inc.) Net Profit

VTYX (Ventyx Biosciences, Inc.) - company brandmark

Ventyx Biosciences specializes in developing immune-boosting agents and therapies for medical pathologies. The company is currently regaining shareholder loyalty following a strategic pivot in its research priorities, with the indicator standing at -0.10. This chart on the GURU.Markets platform illustrates the asset's price action. The business focuses on producing oral medications to combat autoimmune processes, aiming to replace complex injections with more convenient administration forms.

VTYX (Ventyx Biosciences) Net Profit history from 07/04/2022 to 03/14/2026

Analytical breakdowns and data insights for company Ventyx Biosciences, Inc. (VTYX)

- price and consensus price forecast:
Stock Quotes Ventyx Biosciences, Inc|VTYX - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization Ventyx Biosciences, Inc|VTYX - Real Price to Acquire Entire Company
- book capitalization data:
Accounting Value of a Share Ventyx Biosciences|VTYX - Book Capitalization|Market Capitalization to Book Value ventyxbio.com|VTYX - Aggregate Company Assets
- debt and solvency information:
Total Debt to Equity Ratio Ventyx Biosciences|VTYX - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Ventyx Biosciences Inc.|VTYX - Company Total Debt|Debts to Book Capitalization Ventyx Biosciences, Inc|VTYX - Company Long-Term Debt|Company Short-Term Indebtedness Ventyx Biosciences|Immediate Liquidity ventyxbio.com
- net income and valuation multiples indicators:
VTYX - Net Income
Summary company analysis:Ventyx Biosciences
Core merchandise of Ventyx Bio

Professional asset selection begins with the verification of a business's actual operational efficiency. This metric measures the share of net income, adjusted for accounting pauses, as reflected in the final profit of the company on the GURU.Markets platform. Investors should compare this trend with the debt load to avoid overpaying. Licensing contracts with pharma giants ensure the stability of Ventyx Biosciences (VTYX). Such agreements minimize development risks, guaranteeing a long-term inflow of free cash flow.

Main competitors

Net Income argenx BVBA|BNTX (BioNTech SE) - Net Profit|Net Profit Abivax Pharma|Net Income ADMA (ADMA Biologics, Inc.)|PTGX (Protagonist Therapeutics, Inc.) - Final Profit|Net Profit IMVT (Immunovant Corp)|Net Financial Result Kiniksa Corp (KNSA)|GRFS - Company Net Income|adaptivebiotech.com (ADPT) - Net Income|Celldex Therapeutics, Inc. (CLDX) - Company Net Income|Net Income Aurinia Pharmaceuticals Inc|Net Income BCRX|Net Profit Vera Corp|Company Net Income Dianthus Therapeutics (DNTH)|pharvaris.com - Company Profit|Net Profit ABCL (AbCellera Biologics Inc)|Tourmaline Bio Inc (TRML) - Company Net Income|PGEN: Net Income|PHAR: Company Net Income|NKTR: Net Profit|Company Net Income upstreambio.com (UPB)|Company Net Income Zenas Biopharma|Company Profit IMNM (Immunome Inc)|Net Income GOSS (Gossamer Corp)|Profit After Payment of Taxes KALV|Septerna Inc - Net Income|pieris.com (PVLA) - Company Net Income|SVRA: Net Income|RIGL (Rigel Pharma) - Company Profit|ANAB (AnaptysBio Corp) - Net Income|Astria Corp - Final Profit|ENGN (enGene Holdings Inc.) - Net Profit|Company Net Income RAPT|Net Profit JBIO|Net Financial Result Aclaris Therapeutics Inc.|Company Net Income Kyverna KYTX|Tiziana Life Sciences, Ltd. (TLSA) - Company Net Income|CABA - Company Net Income|Net Financial Result theratech.com THTX|AVTX: Net Profit|Net Income Eledon Pharmaceuticals Inc.|AGEN (Agenus Inc) - Net Profit|Climb Bio, Inc (CLYM) - Net Financial Result|Net Profit ZURA|ATYR - Company Net Income|Company Net Income Adagene Inc. ADAG|IMA: Company Profit|Shattuck Therapeutics - Net Profit|Equillium, Inc. (EQ) - Net Income|CNTB: Net Profit|Company Net Income Immunic (IMUX)|Company Net Income Atara Biotherapeutics, Inc.|InflaRx GmbH (IFRX) - Net Financial Result|Net Income XFOR (X4 Pharma)|Company Net Income ACET (adicetbio.com)|Celularity - Net Income|Profit After Payment of Taxes INMB (inmunebio.com)|BRNS: Net Income|Company Net Income Kezar Life Sciences Inc.|SABS (SAB Biotherapeutics, Inc) - Net Income|Company Profit AKTX|Company Net Income Enlivex Therapeutics Ltd|Q32 Bio Corp - Profit After Tax|Net Profit GOVX|EDSA (Edesa Biotech Inc) - Final Profit|Net Profit IBIO (iBio Corp)|Net Profit Carisma Therapeutics Inc CARM|XTLB - Company Net Income|Final Profit BOLT (Bolt Biotherapeutics)|hcwbiologics.com (HCWB) - Company Net Income|Net Income Aptevo Therapeutics Inc.|AIM (AIM ImmunoTech) - Net Profit|Net Profit Aditxt Corp|Net Income GRI (GRI Bio, Inc.)|XRTX (xortx.com) - Final Profit|Net Profit HIND (Vyome Holdings)|Net Financial Result Revelation Biosciences Inc (REVB)|INDP - Company Net Income|BiondVax Pharmaceuticals (SCNI) - Net Income|calcimedica.com (CALI) - Company Net Income|Net Income Affimed N.V.|Net Income ALLK|Net Profit HOOKIPA|Company Net Income IGM Biosciences, Inc. (IGMS)|iTeos Pharma - Company Profit|Net Profit OCEA (Ocean Biomedical, Inc.)|tcbiopharm.com (TCBP) - Company Net Income|THRD: Net Income